Biochem J 2008, 409: 581–9.PubMedCrossRef 43. Zhang Y, Li N, Caron C, et al.: HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003, 22: 1168–79.PubMedCrossRef 44. Blagosklonny MV, Robey R, Sackett DL, et al.: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002, 1: 937–41.PubMed 45. Hubbert C, Guardiola A, Shao R, et al.: HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:
455–8.PubMedCrossRef 46. Dowdy SC, Jiang S, Zhou XC, MEK inhibitor et al.: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006, 5: 2767–76.PubMedCrossRef
47. Zhang D, Sun L, Xian W, et al.: Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest 2010, 90: 436–47.PubMedCrossRef 48. PI3K inhibitor drugs Choi HS, Savard CE, Choi JW, Kuver R, Lee SP: Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts. J Surg Res 2007, 141: 183–91.PubMedCrossRef 49. Liu X, Zhu S, Wang T, et al.: Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med 2005, 2: e354.PubMedCrossRef 50. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA: Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol 2009, 297: L864–70.PubMedCrossRef 51. Atmaca A, Al-Batran SE, Maurer A, et al.: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007, 97: 177–82.PubMedCrossRef 52. Rocca A, Minucci S, Tosti G, et al.: A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer
2009, 100: 28–36.PubMedCrossRef 53. Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A’Hern R: A phase II study to establish the efficacy and toxicity of sodium valproate in patients with MG-132 chemical structure cancer-related neuropathic pain. J Pain Symptom Manage 2001, 21: 204–9.PubMedCrossRef 54. Rodriguez-Menendez V, Tremolizzo L, Cavaletti G: Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone? Curr Cancer Drug Targets 2008, 8: 266–74.PubMedCrossRef 55. Braiteh F, Soriano AO, Garcia-Manero G, et al.: Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008, 14: 6296–301.PubMedCrossRef 56. Munster P, Marchion D, Bicaku E, et al.: Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009, 15: 2488–96.PubMedCrossRef 57.